COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
20/03/2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology
20/03/2025
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and ablation technology has demonstrated potential to more precisely target and [...]
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
20/03/2025
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of [...]
STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light
20/03/2025
HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
20/03/2025
Conference call will be held today, Thursday, March 20 at 9:00 am ET CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
USDA Informs NAPIGEN, Inc. Its CMS Rice Is Not Subject to Regulation
20/03/2025
WILMINGTON, Del., March 20, 2025 (GLOBE NEWSWIRE) -- The U.S. Department of Agriculture has recently issued a Response to the Am I Regulated (AIR) Inquiry from NAPIGEN, Inc. notifying the company that its rice with gene [...]
CorVista Health to Present New Data on Non-Invasive Point of Care Test for Pulmonary Capillary Wedge Pressure Elevation Using Machine Learning at ACC.25
20/03/2025
BETHESDA, Md., March 20, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for pulmonary capillary wedge pressure (PCWP) [...]
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
20/03/2025
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma [...]
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
20/03/2025
Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million 2024 year- [...]
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
20/03/2025
The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer The [...]
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction
20/03/2025
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics [...]
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
20/03/2025
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
20/03/2025
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage [...]
Reflect Scientific Inc. Reports Strong Revenue Growth in 2024
20/03/2025
OREM, Utah, March 20, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (OTC: RSCF), a leading provider of cryogenic cooling and laboratory equipment, is pleased to announce a significant increase in revenue for the [...]
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
20/03/2025
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat [...]
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
20/03/2025
SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces [...]
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
20/03/2025
Key findings support weekly induction of immune cell trafficking by Decoy20, a critical factor in effective cancer immunotherapy NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a [...]
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
20/03/2025
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor
20/03/2025
CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, ( www.pathos.com ), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced the first patient [...]

Pages